CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a bioph

Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) has received a consensus recommendation of "Moderat

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy

CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopha

Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about

Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.07) per share which beat the analyst consen

KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track

Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) and Korro Bio (NASDAQ: KRRO - Get Free Report)

CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biophar

Korro Bio, Inc. (KRRO) might move higher on growing optimism about its earnings prospects, which is

Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The lates

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biophar

Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for

Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Korro Bio (NASDAQ:KRRO) with a Buy a

Citigroup analyst Yigal Nochomovitz initiates coverage on Korro Bio (NASDAQ:KRRO) with a Buy rati

CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biophar

Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.69) per share which beat the analyst consen

Hosted virtual Analyst Day showcasing lead program KRRO-121's potential to be a first-in-class trans

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopha

Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about

Shares of Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) have earned an average rating of "Moderat

Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genet

CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO),  a bio

CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a bioph

Korro Bio reported a net loss of $117.3 million for the year ended December 31, 2025, compared to a

Korro Bio stock rises after earnings as analysts upgrade outlook, highlight new drug candidate, and

Cantor Fitzgerald analyst Steve Seedhouse maintains Korro Bio (NASDAQ:KRRO) with a Overweight and

Raymond James analyst Steven Seedhouse upgrades Korro Bio (NASDAQ:KRRO) from Market Perform to Ou

Korro Bio, Inc. (KRRO) came out with a quarterly loss of $5.32 per share versus the Zacks Consensus

Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(5.32) per share which missed the analyst cons

Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and e

Clear Street analyst Bill Maughan upgrades Korro Bio (NASDAQ:KRRO) from Hold to Buy and raises th

Chardan Capital analyst Keay Nakae upgrades Korro Bio (NASDAQ:KRRO) from Neutral to Buy and raise

HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Korro Bio (NASDAQ:KRRO) from Neutral

Piper Sandler analyst Yasmeen Rahimi upgrades Korro Bio (NASDAQ:KRRO) from Neutral to Overweight

Oppenheimer analyst Kostas Biliouris upgrades Korro Bio (NASDAQ:KRRO) from Perform to Outperform

Cantor Fitzgerald analyst Steve Seedhouse upgrades Korro Bio (NASDAQ:KRRO) from Neutral to Overwe